Zweig Di Menna Associates LLC Arcutis Biotherapeutics, Inc. Transaction History
Zweig Di Menna Associates LLC
- $1.25 Billion
- Q4 2024
A detailed history of Zweig Di Menna Associates LLC transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Zweig Di Menna Associates LLC holds 41,500 shares of ARQT stock, worth $568,965. This represents 0.05% of its overall portfolio holdings.
Number of Shares
41,500Holding current value
$568,965% of portfolio
0.05%Shares
1 transactions
Others Institutions Holding ARQT
# of Institutions
197Shares Held
129MCall Options Held
738KPut Options Held
82K-
Jennison Associates LLC11.7MShares$160 Million0.07% of portfolio
-
Rubric Capital Management LP New York, NY11MShares$150 Million2.84% of portfolio
-
Suvretta Capital Management, LLC New York, NY10.7MShares$147 Million3.92% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$120 Million4.4% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$118 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $825M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...